Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WOW!
SARISSA CAPITAL WINS PROXY CONTEST AGAINST AMARIN BY HUGE LANDSLIDE
Sarissa honored to have received 100 million more votes than Amarin board
Greenwich, CT, February 28, 2023 – Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin’s largest shareholder, we are grateful for the opportunity to remake Amarin for the benefit of all shareholders.
Vascepa, the foundation on which Amarin is built, is a tremendous drug that is compelling for patients and payors – a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa’s rare and highly beneficial profile to unlock tremendous value for all shareholders.
LET’S GET TO WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL SHAREHOLDERS!
Additional Information
Sarissa Capital Management LP (“Sarissa Capital”), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the “Company”) at the general meeting of the Company for the election of Sarissa Capital’s slate of highly-qualified nominees (the “General Meeting”). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.
The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov and at www.freeamarin.com. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital’s proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).
#FreeAmarin
Contact: Dayna Packes
Sarissa Capital Management LP
info@sarissacap.com
invest83838, Yup good move, I bought a few shs as well. I have all the confident in the world that Vascepa will finally get the recognition it deserves and for the patients who need it will finally have access. I wonder how the new board decides to clean house.
I think it was 16 mill shares that Morgan Stanley acquired in the last qtr that was the clue
LBL, This day will be remembered for many years to come. Now let's see how our new best friend coordinates the NEW Amarin 2.0.
I knew you were here all the time just waiting like me.
The market loves Sarissa. A new day for our great company!
To The Moon Alice.
LBL where are you? Finally good news....
invest 83, I am so thrilled there's hope for Vascepa to finally receive the recognition it deserves.
Back up the Truck!!!!
Amarin Corporation Shareholders Have Voted To Elect All 7 Of Sarissa's Nominees, Remove Per Wold-Olsen As Chairman Of Board Effective Immediately
BENZINGA 10:40 AM ET 2/28/2023
Symbol Last Price Change
AMRN 1.71up -0.13 (-7.0652%)
QUOTES AS OF 10:40:58 AM ET 02/28/2023
Sarissa honored to have received 100 million more votes than Amarin board
Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc(NASDAQ:AMRN):
Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin's largest shareholder, we are grateful for the opportunity to remake Amarin for the benefit of all shareholders.
Vascepa, the foundation on which Amarin is built, is a tremendous drug that is compelling for patients and payors - a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa's rare and highly beneficial profile to unlock tremendous value for all shareholders.
LET'S GET TO WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL SHAREHOLDERS!
THANK YOU TO ALL WHO PULLED IT OFF. YEAH
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
BUSINESS WIRE 10:39 AM ET 2/28/2023
Symbol Last Price Change
AMRN 1.71up -0.13 (-7.0652%)
QUOTES AS OF 10:39:03 AM ET 02/28/2023
Sarissa honored to have received 100 million more votes than Amarin(AMRN) board
GREENWICH, Conn.--(BUSINESS WIRE)-- Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc(AMRN) :
Amarin (AMRN) shareholders have sent a loud and clear message repudiating the incumbent Amarin(AMRN) board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin(AMRN) board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin’s largest shareholder, we are grateful for the opportunity to remake Amarin(AMRN) for the benefit of all shareholders.
Vascepa, the foundation on which Amarin(AMRN) is built, is a tremendous drug that is compelling for patients and payors – a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa’s rare and highly beneficial profile to unlock tremendous value for all shareholders.
LET’S GET TO WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL SHAREHOLDERS!
Additional Information
Sarissa Capital Management LP (“Sarissa Capital”), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc(AMRN) (the “Company”) at the general meeting of the Company for the election of Sarissa Capital’s slate of highly-qualified nominees (the “General Meeting”). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.
The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov and at www.freeamarin.com. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital’s proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005961/en/
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
GLOBENEWSWIRE 10:38 AM ET 2/28/2023
Symbol Last Price Change
AMRN 1.7084down -0.1316 (-7.1522%)
QUOTES AS OF 10:37:41 AM ET 02/28/2023
DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc(AMRN) (“Amarin” or the “Company”) today announced that, based on the preliminary voting results provided by its proxy solicitors following the Company’s 2023 General Meeting of Shareholders (the “General Meeting”), Amarin(AMRN) shareholders have voted to elect all seven of Sarissa’s nominees and remove Per Wold-Olsen as Chairman of the Board of Directors, effective immediately.
Amarin’s reconstituted Board will be expanded to 15 directors – Adam Berger, Patrice Bonfiglio, Paul Cohen, Mark DiPaolo, Erin Enright, Keith Horn, Jan van Heek, Odysseas Kostas, Karim Mikhail, Geraldine Murphy, Kristine Peterson, Louis Sterling, Dr. Murray Stewart, Diane Sullivan and Alfonso “Chito” Zulueta. The Board will appoint a new Chairman in due course.
Amarin (AMRN) issued the following statement:
Amarin (AMRN) appreciates the engagement with our shareholders, as well as the valuable insights and perspectives they have shared throughout this process.
While we sought a different outcome, the Board and management team remain focused on executing Amarin’s strategy, particularly at this critical juncture with ongoing pricing and reimbursement negotiations in Europe, International expansion efforts and continued stabilization of our U.S. business, to deliver near- and long-term value. We will work constructively with the newly elected directors toward these shared goals.
We thank Per Wold-Olsen for his unwavering leadership, dedication and oversight during his tenure on the Board and while serving as Chairman.
The election results announced today are considered preliminary until final results are tabulated and certified by the independent Inspector of Elections. Final results will be reported on a Form 8-K that will be filed with the Securities and Exchange Commission.
Advisors
J.P. Morgan is acting as financial advisor. Ropes & Gray LLP and Goodwin Procter LLP are acting as legal advisors to the Company.
About Amarin(AMRN)
Amarin (AMRN) is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in
dar, as long as it takes to do the final count. It's an important meeting so will be 100% sure of the final count.
The stock acts like sh-t but it's mostly retail.
robin, based on my intel Sarissa representative, D.F. King representative and outside counsel will be attending the meeting. I think there will be several PR's today after the meeting. Sarissa will probably be the first if they win.
I wonder why there's no PR from CSL Seqirus.
CCB, they'll have to file an 8K. Maybe we'll find out more with filing. Maybe they'll talk more tomorrow at the ye conf call?
Honestly unless I confirm with CSL I wont believe it. Needs more research and more details.
CCB, maybe a nothing burger like EddingPharma? At least CSL appears to be legitimate.
gusman, I believe the Mitigate trial ends today but not sure about releasing the results.
Now maybe Sarissa will have something to work with....
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
GLOBENEWSWIRE 8:00 AM ET 2/28/2023
Symbol Last Price Change
AMRN 1.84up 0 (0%)
CMXHF 198.976down 0 (0%)
QUOTES AS OF 04:00:00 PM ET 02/27/2023
DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc(AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin(AMRN) will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.
"We are excited to announce this agreement with CSL Seqirus in Australia and New Zealand, a world-class licensing partner for pharmaceuticals,” said Karim Mikhail, President & CEO, Amarin(AMRN). “CSL Seqirus’ highly experienced market access and commercialization teams in Australia and New Zealand are well-positioned to support the pricing and reimbursement efforts, particularly with their strong record in successfully supporting pharmaceutical benefits listings, and eventual marketing and promotion for VAZKEPA and help us to deliver this important medicine to patients in these countries."
According to the Australian Institute of Health and Welfare (AIHW), approximately 1.3 million patients in Australia have established cardiovascular disease (CVD)i and approximately 75% are currently treated with a statin.ii CVD and diabetes are health priorities in NZ. Maori and Pacific peoples have a high incidence of CVD and diabetes and experience significant inequity in both access to medicines and clinical outcomes.
Under the terms of the agreement, CSL Seqirus will in-license VAZKEPA from Amarin(AMRN) and will be responsible for market access and reimbursement efforts, distribution, and commercial promotion for VAZKEPA across Australia and New Zealand. Amarin(AMRN) will receive an upfront payment and be eligible for event-related milestone payments of up to approximately $8 million and additional product-related milestone payments of up to approximately $4 million. Amarin(AMRN) will be responsible for supplying finished product to CSL Seqirus at a profitable transfer price paid to Amarin(AMRN).
About Amarin(AMRN)
Amarin (AMRN) is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin(AMRN) has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and
BRIEF-Amarin And Csl Seqirus Announce Exclusive License And Distribution Agreement To Commercialize Vazkepa In Australia And New Zealand
REUTERS 8:05 AM ET 2/28/2023
Symbol Last Price Change
AMRN 1.84up 0 (0%)
QUOTES AS OF 04:00:00 PM ET 02/27/2023
Feb 28 (Reuters) - Amarin Corporation PLC(AMRN):
* AMARIN AND CSL SEQIRUS ANNOUNCE EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT TO COMMERCIALIZE VAZKEPA (ICOSAPENT ETHYL) IN AUSTRALIA AND NEW ZEALAND
* UNDER TERMS OF AGREEMENT, CSL SEQIRUS WILL IN-LICENSE VAZKEPA FROM AMARIN
* CSL SEQIRUS TO BE RESPONSIBLE FOR MARKET ACCESS, REIMBURSEMENT EFFORTS, DISTRIBUTION, FOR VAZKEPA ACROSS AUSTRALIA, NEW ZEALAND
* AMARIN WILL RECEIVE AN UPFRONT PAYMENT AND BE ELIGIBLE FOR EVENT-RELATED MILESTONE PAYMENTS OF UP TO APPROXIMATELY $8 MILLION
* AMARIN WILL RECEIVE ADDITIONAL PRODUCT-RELATED MILESTONE PAYMENTS OF UP TO APPROXIMATELY $4 MILLION Source text for Eikon: Further company coverage:
(c) Copyright Thomson Reuters 2023. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Robin, legally amarin isn't bound to disclose final votes till the general meeting is over.
One rag, I wish I knew. Watch the share price tomorrow.
raf, they may have an inkling but there are a few sources that still need to be counted in the total. But I would say for the most part they know.
kiwi/capt, proxy votes results should be announced tomorrow. Got it from a contact within DF King.
getting the last words in before the big day!
http://archive.fast-edgar.com/20230227/AD25LG2CZ222MZIZ2H2I2Z42AAS2ZC22Z252
kiwi, definitely if Denner wins Germany will be back on the table using a different approach. He's got the experience and connections to maneuver a win.
newman, yup a perfect example is what happened over the weekend with the CEO Union Pacific, activist hf Soroban Capital called for his head. And he was with Union Pacific for 22 yrs.
jroon, yes indeed the COB always pulls the strings. I don't want to sound like a broken record but KM is over his head. KM can play the victim since PWO was his boss. Denner may want to keep him on as he knows where all the moving parts are in the EU. As someone once said to me "you don't have to like the person you work with".
kiwi, I'm not smart enough to trade this stock. I may buy a few more shs if Denner pulls off a win. I think the odds are pretty good that PWO is ousted. If I decided to buy it's for the long term big one which is the BO that should have happened several yrs ago.
GLTA
robin, we'll know tomorrow and logic tells me they know they lost. But their attitude will be life goes on. If it's only PWO who gets the boot I wonder who will become the COB. AD maybe?? the stock will rally for sure if that takes place.....
tatsumaki, yeah and then he moves on to CINC. In January AstraZeneca announced a buy out.
FYI, be prepared peeps...... The results of the proxy contest will likely be announced the same day of the meeting 2/28 during the day some time.... say a few Hail Marys
retinadoc, KM will not resign he wants to hang around cause when the company is sold he stands to vest over 5mill shs of stock. So Sarissa will probably sack the guy and save the company from more dilution. Whereas a departure prior to the company is sold he will receive a package like JT and stay on as a consultant for a certain period of time.
TTE, please explain the awards you mentioned. I don't understand. Is that in the charter or somewhere else... they can't just issue options or RSU's on demand.
Rose, you're correct in one of Sarissa's PR's made reference to that possibility if amarin didn't start generating revs from the EU.
megc, that's why the stock on the NASDAQ trades with ADR's =American Depositary Receipts cause their charter is in the UK and is foreign.
https://www.marketwatch.com/investing/stock/amrn
nukem, re your last sentence, if Amarin goes after Sarissa with any kind of lawsuit, Amarin will run out of cash defending themselves. That would be a friggin mess.
I'm not jumping to any conclusions till we get the final count. I'm hoping we have a quorum on Tuesday to move forward with the next phase whatever that may be. If no quorum then another general meeting will be called and more of the shareholder's cash will be spent all over again.
Michael, it can be any where btw 2 to 4 days but their earnings date is march 1. So I'm thinking they will announce at cc on 3.1.
jroon, I understand the whole compensation rule based on the DEF 14 filing. But why wait till the middle of the night and after the votes to file?
birdrock, PWO et al waited till the 11th hour before filing their options and RSU. More dilution and once again slimy move after the window closes for voting.